5 Stocks Under $10 That Could Be Your Next
Multibagger (And How to Hunt for Them
Smart)
Last updated: June 2026 | Reading time: ~15 minutes
I'll be honest with you — I used to scroll past stocks under $10 without a second glance. They felt like lottery tickets. Cheap, risky, and a little embarrassing to talk about at a dinner party where everyone's bragging about their S&P 500 index funds.
But then I started paying closer attention to why certain cheap stocks explode in price. And I noticed a pattern that changed how I think about sub-$10 investing entirely.
It's not about finding the cheapest stock you can. It's about finding a company where the fundamentals are quietly and rapidly improving — and the price just hasn't caught up yet.
That gap between reality and price? That's where multibaggers are born.
So today, let's talk about five stocks currently trading under $10 that have recently posted some genuinely impressive earnings numbers, what makes each one worth paying attention to, and — just as importantly — what risks you absolutely need to understand before putting a single dollar in.
Let's get into it.
What Even Is a "Multibagger" — And Why Should You Care?
Before we dive into the stock picks, let's get on the same page about terminology, because "multibagger" gets thrown around a lot without explanation.
A multibagger is simply a stock that returns multiple times your original investment. A 2x return is a "two-bagger." A 10x return? That's a ten-bagger. The legendary investor Peter Lynch popularized the term in his classic book One Up on Wall Street, and it stuck.
Now, here's the thing about hunting multibaggers in the under-$10 space specifically: the math can work in your favor, but so can it work against you.
A $3 stock moving to $9 is a 3x return. A $300 stock doing the same thing? That's... astronomically harder to pull off. Small-cap and micro-cap stocks have more room to run percentage-wise, but they also have more room to fall — fast.
So going in with your eyes wide open is non-negotiable. Which is exactly what we're going to do here.
Why Is the Stock Market Falling Today? 3 Key Reasons Investors Are Watching
The Golden Rule Before You Even Look at a Stock List
Here's something I wish someone had told me earlier: cheap price alone means absolutely nothing.
A stock trading at $2 isn't a bargain just because it's $2. For all you know, it deserves to be at $2. What you're actually hunting for is a stock where the business fundamentals are turning around or accelerating — and the price just hasn't reflected that yet.
The checklist I keep in mind for every sub-$10 pick looks something like this:
- Is quarterly earnings growth accelerating year-over-year?
- Is there a clear, secular industry tailwind behind the business?
- Is there institutional money moving into the stock (not just retail hype)?
- Does the company have a path to profitability — or is it already profitable?
- Is there enough daily trading volume to get in and out without destroying yourself on the bid-ask spread?
That last point matters more than most people realize. Liquidity is your escape hatch. If you can't get out of a trade cleanly, you're not investing — you're trapped. Always look for stocks with at least 1 million shares traded per day on average.
With that framework in mind, let's look at five names that have been catching attention recently.
5 Stocks Under $10 With Strong Earnings Momentum
1. LifeStance Health Group (NASDAQ: LFST) — The Mental
Health Infrastructure Play
What Does LifeStance Actually Do?
LifeStance is one of the largest providers of outpatient mental health care in the United States, offering both in-person and virtual therapy, psychiatry, and psychological testing services. Think of them as the infrastructure layer for mental healthcare — connecting patients with licensed clinicians at scale. As of 2025, they had over 7,424 clinicians on their platform, growing 12% year-over-year.
Earnings & EPS Growth — The Numbers Tell the Story
This is where LFST gets genuinely exciting. The company has been on a rapid recovery trajectory, turning its per-share losses smaller and smaller every quarter until finally flipping positive.
Quarterly EPS Trend (Trailing):
| Quarter | EPS (Reported) | YoY Change |
|---|---|---|
| Q1 2024 | -$0.12 | — |
| Q2 2024 | -$0.10 | Improving |
| Q3 2024 | -$0.07 | Improving |
| Q4 2024 | -$0.04 | Improving |
| Q1 2025 | -$0.02 | Improving |
| Q4 2025 | +$0.03 | Positive! |
| Q1 2026 | +$0.04 | +488% beat vs. estimate |
Q1 2026 was a landmark moment — LFST reported EPS of $0.04, beating analyst expectations of nearly zero by 488%. Revenue for the same quarter came in at $403.5 million, beating estimates by 2.1%.
Annual EPS Forecast (Analyst Consensus):
| Year | EPS Estimate | Growth |
|---|---|---|
| FY2024 (Actual) | $0.07 | Turning positive |
| FY2025 (Actual) | $0.07 | Stabilized |
| FY2026E | $0.13 | +86% YoY |
| FY2027E | $0.21 | +62% YoY |
| FY2028E | $0.31 | +48% YoY |
Revenue Trajectory:
| Year | Revenue | Growth |
|---|---|---|
| FY2023 | $1.056B | — |
| FY2024 | $1.251B | +19% |
| FY2025 | $1.438B | +15% |
| FY2026E | $1.685B | +17% |
| FY2027E | $1.960B | +16% |
Analyst Price Targets & Forecast
17 analysts currently cover LFST with the following consensus:
| Metric | Value |
|---|---|
| Current Price | $7.65 |
| Average Target | $10.17 – $10.52 |
| Low Target | $7.00 |
| High Target | $12.00 |
| Implied Upside | ~33–34% |
| Consensus Rating | Strong Buy (83%) |
| Forward EPS Growth (1yr) | 529% vs. industry avg 10.7% |
Specific analyst moves: UBS raised their target to $12 (from $10), BMO Capital raised to $10 (from $8), and KeyBanc raised to $9 (from $8) — all keeping bullish ratings. The company also authorized a $100 million share repurchase program in early 2026, signaling management confidence.
The Structural Case for Multibagger Potential
Here's the thing about mental health care in America: the supply-demand imbalance is enormous. There are simply not enough mental health providers to serve the people who need them. Telehealth has helped close part of that gap, but the need continues to grow.
As LifeStance scales its clinician network and gets better at managing overhead costs, operating leverage kicks in — meaning revenue grows faster than costs. That's the recipe for margin expansion, and margin expansion in healthcare can be a serious catalyst for stock re-rating.
Key risk to watch: LifeStance operates in a sector heavily affected by insurance reimbursement rates and regulatory changes. Keep an eye on how payer relationships evolve.
2. TAL Education Group (NYSE: TAL) — The Chinese EdTech
Comeback Story
What Does TAL Education Do?
TAL is a Chinese education technology company that trades on the New York Stock Exchange. It provides tutoring, enrichment programs, and increasingly AI-powered educational tools and devices. If you followed Chinese edtech stocks back in 2021, you probably remember the sector getting absolutely decimated by Chinese regulatory crackdowns on academic tutoring. TAL was one of the hardest hit.
But here's where it gets interesting.
Earnings & EPS Growth — One of the Strongest Rebounds Out There
TAL's earnings recovery has been nothing short of remarkable. After years of losses driven by the 2021 regulatory crackdown, the company reinvented its model and came roaring back.
Quarterly EPS Trend:
| Quarter | EPS (Reported) | EPS Estimate | Surprise |
|---|---|---|---|
| Q1 FY2025 | $0.06 | $0.04 | +50% |
| Q2 FY2025 | $0.02 | $0.07 | Miss |
| Q3 FY2025 | $0.24 | $0.16 | +50% beat |
| Q4 FY2025 (Jan 2026) | $0.25 | $0.077 | +225% beat |
| Q3 FY2026 | $0.23 | — | +466% YoY |
That Jan 2026 quarter was a stunner — EPS of $0.25 against an estimate of just $0.077, a beat of over 225%. Year-over-year EPS growth clocked in at 108%.
Annual EPS Forecast:
| Year | EPS Estimate | Growth |
|---|---|---|
| FY2024 (Actual) | -$0.01 | Loss |
| FY2025 (Actual) | $0.14 | Turnaround |
| FY2026E | $0.44 | +214% YoY |
| FY2027E | $0.71 | +61% YoY |
Revenue Trajectory:
| Year | Revenue | Growth |
|---|---|---|
| FY2023 | $988M | — |
| FY2024 | $1.49B | +51% |
| FY2025 | $2.25B | +51% |
| FY2026 (Actual) | $3.01B | +34% YoY |
| FY2027E | $3.87B | +29% |
Full year FY2026 net income came in at $530.8 million — up $446 million from FY2025. Profit margin expanded to 18% from just 3.8% the prior year.
Analyst Price Targets & Forecast
| Metric | Value |
|---|---|
| Current Price | ~$11.25 |
| Average Target (TipRanks) | $15.31 |
| Low Target | $11.54 |
| High Target | $18.00 |
| Implied Upside | ~36% |
| Consensus Rating | Buy |
| EPS Growth Rate (3yr fwd) | 28.8% per year |
| Revenue Growth Rate (3yr fwd) | 16.2% per year |
JPMorgan upgraded TAL to Overweight with a $16 target. Goldman Sachs holds a Buy with a $13.20 target. 21 analysts cover the stock with a bullish skew.
What Could Drive This Higher?
The AI-powered educational device market in China is still in early innings. TAL's pivot to AI learning devices and non-academic enrichment has completely reset its business model — and the numbers prove it's working.
Key risk to watch: This is a Chinese company subject to U.S.-China geopolitical tension, potential delisting risks, and Chinese government regulatory changes. Size your position accordingly.
3. Custom Truck One Source (NYSE: CTOS) — Where AI
Infrastructure Meets Specialized Equipment
What Does CTOS Do?
Custom Truck One Source rents and sells specialized heavy trucks and equipment — the kind used in telecom tower work, electric grid maintenance, and increasingly, data center construction. Think boom cranes, aerial work platforms, and utility trucks on job sites where power lines go up or fiber gets laid. CTOS makes money by providing that specialized fleet to the companies doing that work.
Earnings & EPS Growth — Approaching a Major Profitability Flip
CTOS has been unprofitable but is on a clear trajectory toward that critical inflection point where losses turn to profits. That moment changes everything for institutional investor eligibility and how the market values the stock.
Quarterly EPS Trend:
| Quarter | EPS (Reported) | EPS Estimate | Beat/Miss |
|---|---|---|---|
| Q1 2024 | -$0.06 | -$0.01 | Miss |
| Q2 2024 | -$0.10 | -$0.02 | Miss |
| Q3 2024 | -$0.07 | -$0.03 | Miss |
| Q4 2024 | +$0.12 | +$0.04 | Beat |
| Q1 2025 | -$0.08 | -$0.06 | Miss |
| Q2 2025 | -$0.13 | -$0.05 | Miss |
| Q1 2026 | -$0.02 | -$0.05 | Beat by 60% |
Q1 2026 showed clear improvement — loss narrowing to just $0.02 per share, beating estimates by 60%. Revenue for the same quarter held strong in the $420–460M range.
Annual EPS Forecast:
| Year | EPS Estimate | Status |
|---|---|---|
| FY2024 (Actual) | -$0.11 | Loss |
| FY2025 (Actual) | -$0.23 | Loss (widened) |
| FY2026E | +$0.11 | Profit flip |
| FY2027E | +$0.28 | Growing |
This is the key thesis — the jump from -$0.23 to +$0.11 in a single year is a complete business-model inflection. Post-Q1 2026, analysts raised their EPS estimates by 86%.
Revenue Trajectory:
| Year | Revenue | Growth |
|---|---|---|
| FY2023 | $1.684B | — |
| FY2024 | $1.986B | +18% |
| FY2025 | $1.985B | Flat |
| FY2026E | $2.050B | +3.3% |
| FY2027E | $2.190B | +6.8% |
Revenue growth is slowing vs. its historical 16% pace, which is worth monitoring. The real story in 2026 is margin expansion and the profit flip, not top-line fireworks.
Analyst Price Targets & Forecast
| Metric | Value |
|---|---|
| Current Price | ~$6.14 |
| Average Target | $7.50 – $9.79 |
| Low Target | $6.06 |
| High Target | $9.79 |
| Implied Upside | 22–60% |
| Consensus Rating | Buy / Strong Buy |
| Institutional Ownership | 90.07% |
| Revenue CAGR (3yr) | 7% |
| Operating Income CAGR (3yr) | 12% |
Analyst consensus price target was raised 20% to $9.79 following Q1 2026 results. 90% institutional ownership is a huge signal — the big money is already in.
The Megatrend Tailwind Here Is Hard to Ignore
AI data centers need massive amounts of power. The electric grid needs modernization. 5G towers need to be built and maintained. Every single one of those projects needs the specialized trucks and equipment that CTOS provides. That's not a short-term trend — it's a decade-long tailwind, at minimum.
Key risk to watch: High net leverage at 4.66x, declining backlog, and cyclical end markets. Tariff headwinds on equipment sourcing could also pressure margins.
4. Octave Specialty Group (NYSE: OSG) — A Micro-Cap With
Big Growth Projections
What Does OSG Do?
Octave Specialty Group — formerly known as Ambac Financial — rebranded in November 2025 after a dramatic business transformation. The company sold its legacy financial guarantee business and acquired ArmadaCare, emerging as a pure-play specialty property & casualty insurance and insurance distribution company. It's a genuine phoenix story, and the market hasn't fully priced it in yet.
Earnings & EPS Growth — Losses Narrowing Fast
OSG is still loss-making, but the pace of improvement is what makes it interesting. Revenue is exploding while losses are shrinking rapidly — a classic pre-profitability growth setup.
Quarterly EPS Trend:
| Quarter | EPS (Reported) | YoY Change |
|---|---|---|
| Q1 2025 | -$0.58 | — |
| Q2 2025 | -$0.45 | Improving |
| Q3 2025 | -$0.40 | Improving |
| Q4 2025 | -$0.35 | Improving |
| Q1 2026 | -$0.15 | +74% improvement YoY |
Q1 2026: EPS beat analyst estimates by 38%. Revenue came in at $104.2 million — up 66% year-over-year — and beat estimates by 23%. Net loss narrowed by 75% from the same quarter a year earlier.
Annual EPS Forecast:
| Year | EPS Estimate | Status |
|---|---|---|
| FY2024 (Actual) | -$2.70 | Deep loss |
| FY2025 (Actual) | -$1.78 | Improving |
| FY2026E | -$0.60 | Narrowing fast |
| FY2027E | +$0.20 | Path to profit |
Revenue Trajectory:
| Year | Revenue | Growth |
|---|---|---|
| FY2023 | $175M | — |
| FY2024 | $241M | +38% |
| FY2025 | $251M | +4.3% |
| FY2026E | $290M | +15.5% |
| FY2027E | $330M | +14% |
The insurance distribution segment specifically grew 92% year-over-year in Q1 2026 — that's the rocket engine inside OSG right now.
Analyst Price Targets & Forecast
| Metric | Value |
|---|---|
| Current Price | ~$5.55 |
| Average Target | $15.33 |
| Low Target | $4.62 |
| High Target | $15.00 |
| Implied Upside | 176% |
| Consensus Rating | Strong Buy (3 analysts) |
| Revenue CAGR (2yr fwd) | 14% per year |
| Industry Revenue CAGR | 2.6% (OSG vastly outpacing) |
A 176% implied upside from current prices is an extraordinary number — even discounting for analyst optimism, there's a wide gap between price and perceived value here.
Why Micro-Caps Like This Can Have Explosive Runs
Here's a dynamic that plays out repeatedly in the small-cap world: a company grows rapidly but stays under the radar of major Wall Street research desks. Then when a Goldman or Jefferies analyst initiates formal coverage, institutional money pours in and the stock reprices dramatically. OSG appears to be in that pre-coverage phase.
Key risk to watch: Still loss-making, thin analyst coverage (only 3 analysts), legacy Ambac liabilities, and illiquid micro-cap trading dynamics. Do not put more in than you can genuinely afford to lose.
5. AdaptHealth Corp. (NASDAQ: AHCO) — Home Medical
Equipment for an Aging America
What Does AdaptHealth Do?
AdaptHealth distributes home medical equipment — sleep therapy devices (CPAP machines), diabetes supplies, mobility equipment, and specialized items that patients need at home rather than in a clinical setting. Their customers are typically elderly or managing chronic conditions.
This is a boring business in the best possible way. People need this stuff regardless of what the economy is doing. That's the kind of demand profile that makes for durable, predictable revenue.
Earnings & EPS Growth — The Steady Compounder
Unlike the high-drama recovery stories above, AHCO is a steadier ship. It's consistently growing earnings and has been beating analyst estimates with quiet reliability.
Quarterly EPS Trend:
| Quarter | EPS (Reported) | YoY Change |
|---|---|---|
| Q1 2024 | $0.10 | — |
| Q2 2024 | $0.12 | — |
| Q3 2024 | $0.14 | — |
| Q4 2024 | $0.25 | — |
| FY2024 Full Year | $0.61 | Beat estimates by 16% |
| FY2025 Full Year | $0.87 | +42% YoY |
FY2024 EPS of $0.61 beat analyst expectations by 16%, prompting a wave of analyst target upgrades. The consensus price target jumped 14% to $12.83 immediately after results.
Annual EPS Forecast:
| Year | EPS Estimate | Growth |
|---|---|---|
| FY2024 (Actual) | $0.61 | Base |
| FY2025 (Actual) | $0.87 | +43% |
| FY2026E | $1.03 | +18% |
| FY2027E | $1.30 | +26% |
| FY2028E | $1.55 | +19% |
Revenue Trajectory:
| Year | Revenue | Growth |
|---|---|---|
| FY2023 | $3.20B | — |
| FY2024 | $3.30B | +3% |
| FY2025E | $3.27B | Flat |
| FY2026E | $3.42B | +4.6% |
| FY2027E | $3.57B | +4.4% |
Revenue growth is slow but the earnings growth is accelerating — which means margins are expanding. That's the value creation engine here.
Analyst Price Targets & Forecast
| Metric | Value |
|---|---|
| Current Price | ~$12.24 |
| Average Target | $12.88 |
| Low Target | $9.50 |
| High Target | $17.00 |
| Implied Upside | ~5–8% (near fair value) |
| Consensus Rating | Buy (6 Buy, 2 Hold — 8 analysts) |
| EPS Growth Rate (fwd) | 16.2% per year |
| US Market Avg EPS Growth | 14.3% per year |
Truist raised their target to $14, Jefferies to $11, while Deutsche Bank trimmed to $9.50. The stock is currently trading close to analyst consensus fair value — so the upside here is more modest than the other four names, but the risk profile is also meaningfully lower.
The Demographic Wind at Its Back
America is aging. That's not a forecast — it's a mathematical certainty. The baby boomer generation is fully in retirement, and demand for home medical equipment will only grow as they age further into their 70s and 80s.
Home healthcare is also increasingly preferred by insurance payers, because keeping patients out of hospitals is dramatically cheaper. That alignment between patient preference, payer incentive, and demographic demand makes this a compelling long-term hold.
Key risk to watch: Legacy debt load is real. Watch the debt-to-equity ratio and free cash flow generation closely each quarter.
Side-by-Side Comparison: All 5 Stocks at a Glance
Here's a quick reference table so you can compare all five names in one shot:
| Stock | Ticker | Price | Avg Target | Upside | Rating | FY2026 EPS Est. | EPS Growth | Risk Level |
|---|---|---|---|---|---|---|---|---|
| LifeStance Health | LFST | $7.65 | $10.17 | +33% | Strong Buy | $0.13 | +529% (1yr fwd) | Medium |
| TAL Education | TAL | $11.25 | $15.31 | +36% | Buy | $0.44 | +214% YoY | High |
| Custom Truck | CTOS | $6.14 | $7.75 | +26% | Buy | $0.11 | Flip to profit | Medium |
| Octave Specialty | OSG | $5.55 | $15.33 | +176% | Strong Buy | -$0.60 | Losses narrowing | High |
| AdaptHealth | AHCO | $12.24 | $12.88 | +8% | Buy | $1.03 | +18% YoY | Low-Med |
How to Approach These Stocks Without Blowing Up Your
Portfolio
Okay, we've looked at five interesting names with real data behind them. Now let me share some honest thoughts on how to approach this category of investing responsibly.
Position Sizing Is Everything
I can't stress this enough: stocks under $10, especially micro-caps, should never make up a disproportionate chunk of your portfolio. A reasonable approach might be to allocate 5-15% of your total portfolio to higher-risk, higher-upside plays like these — and then diversify even within that slice across multiple names.
If one of these stocks goes to zero (which can absolutely happen), you want that to sting but not devastate.
Do Your Own Research — Seriously
The five names above are starting points for research, not buy recommendations. Before putting any money into any of these stocks, I'd encourage you to:
- Read the most recent quarterly earnings report (10-Q) directly from the SEC's EDGAR database
- Listen to the most recent earnings call (transcripts are freely available on Seeking Alpha and similar sites)
- Understand the competitive landscape for the company's products or services
- Check the institutional ownership trends — are big funds buying or selling?
Watch the Volume Every Single Day
Liquidity matters enormously in small-cap stocks. A stock might look like it's up 8% today — but if the volume is only 200,000 shares, that move can reverse just as fast. Focus on names with consistent, high daily volume so you can enter and exit positions cleanly.
A Quick Word on Tax Efficiency When Swing Trading Small
Caps
If you're buying and selling these stocks within a year, your gains will be taxed at ordinary income rates — not the lower long-term capital gains rate. For active traders in higher tax brackets, this can significantly eat into your actual returns.
Consider holding winning positions for at least 12 months when possible to qualify for long-term capital gains treatment. Always talk to a tax professional about your specific situation.
What to Watch For in the Coming Quarters
If you're keeping tabs on any of these names, here's what I'd be watching most closely in upcoming earnings reports:
- LFST: Clinician headcount growth, gross margin per visit, and EBITDA guidance revisions
- TAL: Revenue from AI learning devices vs. legacy tutoring programs, margin trajectory
- CTOS: Profit flip confirmation, debt paydown pace, and infrastructure order flow
- OSG: Insurance distribution revenue growth (the 92% YoY segment), path to EPS breakeven
- AHCO: Free cash flow generation, net debt reduction, and any payer mix changes
Earnings momentum can turn quickly in small caps. One bad quarter can reset a thesis, and one blowout quarter can send a stock up 30% in a day. Staying informed is not optional in this space.
Conclusion: The Patient Approach Wins in Small-Cap Land
Here's what I've learned after spending real time in the under-$10 stock universe: the people who do best aren't the ones who pick the most stocks or trade the most frequently. They're the ones who do deep research on a handful of names, size their positions responsibly, and have the patience to let a thesis play out over 12-24 months.
The five stocks we talked about today — LifeStance Health, TAL Education, Custom Truck One Source, Octave Specialty Group, and AdaptHealth — each represent a different type of opportunity and a different risk profile. That kind of diversification across themes can help smooth out the volatility inherent in any single name.
None of these are guaranteed winners. But if you're willing to do the research, understand the risks, and invest with appropriate position sizes, the sub-$10 space can offer asymmetric upside that's genuinely hard to find among large-cap stocks.
Just remember the golden rule: it's not about the price of the share. It's about what the business is doing — and where it's headed.
Happy hunting — and always invest smart.
Disclaimer:
This article is for informational and educational purposes only and does not constitute financial, investment, or tax advice. All data, analyst price targets, EPS estimates, and revenue forecasts cited are sourced from publicly available Wall Street consensus data as of June 2026 and are subject to change. All investing involves risk, including the possible loss of principal. Sub-$10 and micro-cap stocks carry additional risks including lower liquidity, higher volatility, and less regulatory oversight. Always conduct your own due diligence and consult a qualified financial advisor before making any investment decisions. The author may or may not hold positions in the stocks mentioned at the time of publication.
Post a Comment